Medical
SS Innovations sent SSi Mantra to the FDA for review under the 510(k) route, covering general, urology, bowel, gynecology and heart surgery. It is not yet cleared.
A dated step forward on the record · Company-reported
What the source says
“Those include general, urological, colorectal, gynecological and cardiac surgery.”
What it means
SSi Mantra, from SS Innovations, is at stage 4 of 5 on our ladder: paying customers. Its stage is set by other milestones on its record; this one adds to the history. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on SSi Mantra
- SS Innovations installed 30 new robots in April to June 2026, bringing the total to 224 in 12 countries and more than 12,200 surgeries.
- The company's CEO, in Georgetown, Guyana, did part of a heart operation on a patient in Indore, India, about 12,500 miles away, with surgeons at the patient's bedside.
- SS Innovations raised $18.6 million by selling shares privately, to prepare for the US and EU markets.
- The company said more than 3,800 surgeries had been done with SSi Mantra, including over 200 heart operations.
- Surgeons used SSi Mantra for remote operations on an animal 5 km away, the company's first telesurgery.
- SS Innovations, which already had approval from Indian regulators, filled its first order outside India: a robot for Aster Hospital in Dubai.